Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Sarcoma × Leucovorin × Clear all

Phase

Phase 1 5 Phase 2 4 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Dermatologic 1

Conditions

Colorectal Neoplasms 33 Pancreatic Neoplasms 19 Colonic Neoplasms 10 Rectal Neoplasms 8 Stomach Neoplasms 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Neoplasms 6 Neoplasm Metastasis 6 Gastrointestinal Neoplasms 6 Esophageal Neoplasms 6 Carcinoma, Non-Small-Cell Lung 5 Biliary Tract Neoplasms 5 Advanced Solid Tumors 4 Triple Negative Breast Neoplasms 3 Melanoma 3 Endometrial Neoplasms 3 Carcinoma, Squamous Cell 3 Adenocarcinoma Of Esophagus 3 Squamous Cell Carcinoma of Head and Neck 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Liver Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Carcinoma, Transitional Cell 2 Carcinoma, Hepatocellular 2 Carcinoma 2 Advanced Solid Tumor 2 Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC 1 Solid Cancer 1 Small Cell Lung Carcinoma 1

Interventions

Gemcitabine 15 pembrolizumab 13 Doxorubicin 13 Radiotherapy 12 Docetaxel 9 Nivolumab 8 Filgrastim 7 Cyclophosphamide 7 pazopanib 6 Ifosfamide 6 130-nm albumin-bound paclitaxel 5 Temozolomide 4 Irinotecan 4 Ipilimumab 4 Imatinib Mesylate 4 Albumin-Bound Paclitaxel 4 talimogene laherparepvec 3 surufatinib 3 pegfilgrastim 3 eribulin 3 atezolizumab 3 Vinorelbine 3 Sirolimus 3 Peripheral Blood Stem Cell Transplantation 3 PM 01183 3 Drug Therapy 3 Cisplatin 3 toripalimab 2 spartalizumab 2 selinexor 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03009058 2024-11-25

MODULATE

Immodulon Therapeutics Ltd

Phase 1/2 Terminated

2 enrolled 7 charts

DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡